8-K: Inhibrx Biosciences Holds Annual Meeting, Elects Directors
Submission of Matters to a Vote of Security Holders
Inhibrx Biosciences, Inc. held its 2026 Annual Meeting of Stockholders, where directors were elected and the appointment of its independent registered public accounting firm was ratified.
Summary
- Inhibrx Biosciences, Inc. conducted its 2026 Annual Meeting of Stockholders on June 3, 2026, in a virtual format.
- A quorum of approximately 79% of outstanding shares entitled to vote was present.
- Shareholders voted on two proposals: the election of Class II directors and the ratification of the appointment of BDO USA, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Douglas G. Forsyth and Kimberly Manhard were elected as Class II directors, each to serve until the 2029 Annual Meeting.
- The appointment of BDO USA, P.C. as the independent auditor for fiscal year 2026 was ratified.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, reflecting routine corporate governance activities with strong shareholder participation and approval, indicating stability.
Positives
- A strong quorum of approximately 79% of outstanding shares was present at the annual meeting, indicating significant shareholder engagement.
- Both director nominees, Douglas G. Forsyth and Kimberly Manhard, received a substantial majority of votes in favor of their election.
- The appointment of BDO USA, P.C. as the independent auditor for fiscal year 2026 was overwhelmingly ratified with minimal opposition.
Future Outlook
The filing does not contain specific forward-looking financial guidance. The election of directors and ratification of auditors are standard corporate governance procedures.
Industry Context
StockSavvy.ai notes that the smooth execution of annual meetings and the ratification of auditor appointments are fundamental to maintaining investor confidence and regulatory compliance within the biotechnology sector.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Election | Election of Douglas G. Forsyth and Kimberly Manhard as Class II directors. | June 3, 2026 | Ensures continuity in board leadership and strategic oversight. |
| Auditor Appointment Ratification | Ratification of BDO USA, P.C. as the independent registered public accounting firm for fiscal year 2026. | June 3, 2026 | Maintains independent financial oversight and compliance with auditing standards. |
Stakeholder Impact
- Shareholders: Confirmation of board composition and independent audit oversight provides assurance of governance.
Next Steps
- Douglas G. Forsyth and Kimberly Manhard will serve as Class II directors until the 2029 Annual Meeting of Stockholders.
- BDO USA, P.C. will serve as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.
Key Dates
| Date | Description |
|---|---|
| April 7, 2026 | Record date for determining stockholders entitled to vote at the Annual Meeting. |
| April 23, 2026 | Date of filing of the Company's definitive proxy statement. |
| June 3, 2026 | Date of the 2026 Annual Meeting of Stockholders and the date of this report. |
| December 31, 2026 | Fiscal year end for which BDO USA, P.C. was appointed as the independent registered public accounting firm. |
| 2029 | Year until which the elected Class II directors will serve. |
Keywords
Inhibrx Biosciences, Annual Meeting, Stockholders, Director Election, Independent Auditor, BDO USA, P.C., Corporate Governance, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.